Company news

Radiopharm Theranostics Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy

July 22, 2026

RAD Achieves Partial Response in Phase 1 Trial of RAD204

July 21, 2026

Radiopharm Theranostics Reports Business Update

April 23, 2026

Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors at American Association for Cancer Research 2026

April 20, 2026

Radiopharm Theranostics Completes Enrollment in U.S. Phase 2b Imaging Trial of RAD 101 for Diagnosis of Brain Metastases

April 16, 2026

RAD Completes Enrollment in Phase 2b Trial of RAD 101

April 15, 2026

Radiopharm Theranostics Advances to Cohort 3 in 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial

April 8, 2026

RAD202 Phase 1 HEAT Trial Advances to Dose Level 3

April 7, 2026

Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S.

April 7, 2026

Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate Cancer

March 27, 2026

RAD Doses First Patient in RAD 402 Phase 1 Clinical Study

March 26, 2026

Radiopharm Theranostics Achieves Primary Endpoint In 90% of Patients At Second Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases

March 24, 2026

RAD101 2nd interim Ph.2b data - 90% achieve primary endpoint

March 23, 2026

Half Year Report and Appendix 4D 31 December 2025

February 27, 2026

Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

February 25, 2026

Radiopharm Theranostics Doses First Patient in Phase 1/2a Clinical Study of BetaBart (RV-01)

February 24, 2026

RAD Doses First Patient in 177Lu-BetaBart (RV-01) Study

February 23, 2026

Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates

January 28, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

January 27, 2026

Presenting on Emerging Growth Conference 89 Day 2 on January 22; Register to live stream

January 21, 2026

Presenting on Emerging Growth Conference 89 Day 1 on January 21; Register to live stream

January 20, 2026

RAD Increases Ownership in Radiopharm Ventures to 87.5%

January 12, 2026

Radiopharm Theranostics Achieves Primary Endpoint in 92% of Patients at Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases

December 15, 2025

RAD101 interim Phase 2b data - 92% achieve primary endpoint

December 14, 2025

Amendment to Annual Report by Foreign Issuer (Form 20-F/A)

December 10, 2025

Radiopharm Theranostics Receives Approval to Initiate Phase 1 Therapeutic Trial of RAD 402 (KLK3-mAb with Tb161) in Advanced Prostate Cancer

November 18, 2025

RAD Approval for Phase 1 Therapeutic Trial of RAD 402

November 17, 2025

Radiopharm Theranostics Announces 50% Enrollment in Phase 2b Clinical Trial of RAD101 Imaging in Brain Metastases

November 17, 2025

RAD Announces 50% Enrollment in Phase 2b Trial of RAD101

November 16, 2025

Radiopharm Theranostics starts enrollment of the Third Cohort of Phase 1 Dose Escalation Clinical Trial of 177Lu-RAD204

November 12, 2025

RAD starts enrollment of 3rd Cohort of Phase 1 177Lu-RAD204

November 11, 2025

Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing

November 5, 2025

RADX: Program and Financial Updates

November 3, 2025

CORRECTION -- International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025

October 31, 2025

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025

October 29, 2025

Prospectus

October 20, 2025

RAD completes A$35 M Placement and launches A$5 M SPP

October 19, 2025

Trading Halt

October 15, 2025

Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee (DSMC) to Accelerate 177Lu-RAD202 Phase 1 ‘HEAT’ Dose Escalation Clinical Trial

October 1, 2025

Radiopharm received approval for RAD 202 trial acceleration

September 30, 2025

SPL: Research & Option Agreement with Radiopharm Theranostics

September 30, 2025

Annual Report for Fiscal Year Ending June 30, 2025 (Form 20-F)

September 18, 2025

Appendix 4E and Preliminary Final Report

August 29, 2025

Radiopharm Theranostics reports Fiscal Year 2025 Financial Results and Business Update

July 29, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

July 28, 2025

RAD receives IND approval from US FDA for Betabart (RV-01)

July 27, 2025

Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

July 22, 2025

Radiopharm Theranostics and Cyclotek Sign Clinical Supply Agreement for ¹⁶¹Tb-KLK3-mAb Phase I Clinical Trial in Australia

June 24, 2025

Radiopharm Theranostics Granted U.S. Food and Drug Administration Fast Track Designation for RAD101 Imaging in Brain Metastases

June 11, 2025

RAD Granted US FDA Fast Track for RAD101 Metastases Imaging

June 10, 2025

← Newer news releases · Older news releases →

Decks

The 5 newest of 28 decks. Every deck is listed under its year.